18F-FDG PET Imaging of Myocardial Viability in an Experienced Center with Access to 18F-FDG and Integration with Clinical Management Teams: The Ottawa-FIVE Substudy of the PARR 2 Trial

被引:109
|
作者
Abraham, Arun [1 ,2 ]
Nichol, Graham [3 ]
Williams, Kathryn A. [1 ,2 ]
Guo, Ann [1 ,2 ]
deKemp, Robert A. [1 ,2 ]
Garrard, Linda [1 ,2 ]
Davies, Ross A. [1 ,2 ]
Duchesne, Lloyd [1 ,2 ]
Haddad, Haissam [1 ,2 ]
Chow, Benjamin [1 ,2 ]
DaSilva, Jean [1 ,2 ]
Beanlands, Rob S. B. [1 ,2 ]
机构
[1] Univ Ottawa, Inst Heart, Natl Cardiac PET Ctr, Ottawa, ON K1Y 4W7, Canada
[2] Univ Ottawa, Inst Heart, Div Cardiol, Cardiovasc Res Methods Ctr, Ottawa, ON K1Y 4W7, Canada
[3] Univ Washington, Harborview Ctr Prehosp Emergency Care, Seattle, WA 98195 USA
关键词
cardiology (clinical); PET; fluorodeoxyglucose; LV dysfunction; viability; LEFT-VENTRICULAR DYSFUNCTION; POSITRON-EMISSION-TOMOGRAPHY; CORONARY-ARTERY-DISEASE; RANDOMIZED-TRIALS; REVASCULARIZATION; PROGNOSIS; MORTALITY; SUBGROUP; INFARCTION; SURVIVAL;
D O I
10.2967/jnumed.109.065938
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
F-18-FDG PET may assist decision making in ischemic cardiomyopathy. The PET and Recovery Following Revascularization (PARR 2) trial demonstrated a trend toward beneficial outcomes with PET-assisted management. The substudy of PARR 2 that we call Ottawa-FIVE, described here, was a post hoc analysis to determine the benefit of PET in a center with experience, ready access to F-18-FDG, and integration with clinical teams. Methods: Included were patients with left ventricular dysfunction and suspected coronary artery disease being considered for revascularization. The patients had been randomized in PARR 2 to PET-assisted management (group 1) or standard care (group 2) and had been enrolled in Ottawa after August 1, 2002 (the date that on-site F-18-FDG was initiated) (n = 111). The primary outcome was the composite endpoint of cardiac death, myocardial infarction, or cardiac rehospitalization within 1 y. Data were compared with the rest of PARR 2 (PET-assisted management [group 3] or standard care [group 4]). Results: In the Ottawa-FIVE subgroup of PARR 2, the cumulative proportion of patients experiencing the composite event was 19% (group 1), versus 41% (group 2). Multivariable Cox proportional hazards regression showed a benefit for the PET-assisted strategy (hazard ratio, 0.34; 95% confidence interval, 0.16-0.72; P = 0.005). Compared with other patients in PARR 2, Ottawa-FIVE patients had a lower ejection fraction (25% +/- 7% vs. 27% +/- 8%, P = 0.04), were more often female (24% vs. 13%, P = 0.006), tended to be older (64 +/- 10 y vs. 62 +/- 10 y, P = 0.07), and had less previous coronary artery bypass grafting (13% vs. 21%, P = 0.07). For patients in the rest of PARR 2, there was no significant difference in events between groups 3 and 4. The observed effect of F-18-FDG PET-assisted management in the 4 groups in the context of adjusted survival curves demonstrated a significant interaction (P = 0.016). Comparisons of the 2 arms in Ottawa-FIVE to the 2 arms in the rest of PARR 2 demonstrated a trend toward significance (standard care, P = 0.145; PET-assisted management, P = 0.057). Conclusion: In this post hoc group analysis, a significant reduction in cardiac events was observed in patients with F-18-FDG PET-assisted management, compared with patients who received standard care. The results suggest that outcome may be benefited using F-18-FDG PET in an experienced center with ready access to F-18-FDG and integration with imaging, heart failure, and revascularization teams.
引用
收藏
页码:567 / 574
页数:8
相关论文
共 50 条
  • [31] Imaging in myositis: MRI or 18F-FDG PET/CT?
    Ilgen, Ufuk
    Emmungil, Hakan
    CLINICAL RHEUMATOLOGY, 2022, 41 (07) : 2253 - 2254
  • [32] PET/CT imaging with 18F-FDG in Castleman disease
    Delgado, A.
    Mesa, J.
    Guayambuco, S.
    Rodriguez, T.
    Fernandez, I.
    Rodeno, E.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2016, 35 (03): : 200 - 201
  • [33] 18F-FDG PET/CT Imaging of Pulmonary Hamartomas
    Usmani, Sharjeel
    Jain, Anjali
    Akhter, Syed M. J.
    Al Riyami, Khulood
    Abubakar, Sofiullah
    Al Busaidi, Asiya
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (11) : E537 - E538
  • [34] 18F-FDG PET/CT Imaging in Adrenal Cryptococcosis
    Jain, Tarun Kumar
    Karunanithi, Sellam
    Bal, Chandrasekhar
    Kumar, Rakesh
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (04) : E194 - E195
  • [35] Best Practices for Preclinical 18F-FDG PET Imaging
    Kelada, Olivia
    Tseng, Jen-Chieh
    Peterson, Jeffrey
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [36] The optimization of quality of cardiac 18F-FDG PET imaging
    Nifontov, E. M.
    Ryzhkova, D. V.
    Tyutin, L. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S375 - S376
  • [37] Pulmonary Carcinosarcoma: 18F-FDG PET/CT Imaging
    Chuang, Tzyy-Ling
    Lai, Chun-Liang
    Chang, Shu-Mei
    Wang, Yuh-Feng
    CLINICAL NUCLEAR MEDICINE, 2012, 37 (11) : 1105 - 1107
  • [38] 18F-FDG PET/CT imaging in tendon xanthomatosis
    Kim, Dae-Weung
    Kim, Chang-Guhn
    Park, Soon-Ah
    Na, Young Cheon
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (07) : 1403 - 1404
  • [39] 18F-FDG PET/CT IMAGING IN ORBITAL TUMOURS
    Salman, K.
    Fawzy, A.
    Munshi, T.
    INTERNAL MEDICINE JOURNAL, 2012, 42 : 29 - 29
  • [40] 18F-FDG PET/CT Imaging Findings of Leprosy
    Shao, Dan
    Deng, Yue-Ting
    Shao, Fu-Qiang
    Liang, Jia-Wei
    Wang, Shu-Xia
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (05) : E236 - E238